Form 4 Maze Therapeutics, Inc. For: Jun 01 Filed by: Bernstein Harold Jun 3, 2026 05:01PM
Form 4 Maze Therapeutics, Inc. For: May 14 Filed by: Bernstein Harold May 18, 2026 05:04PM
Form 4 Maze Therapeutics, Inc. For: Apr 01 Filed by: Bernstein Harold Apr 2, 2026 04:08PM
Maze Therapeutics reports positive Phase 2 trial data for kidney drug Mar 25, 2026 07:00AM
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease Mar 25, 2026 07:00AM


Mar 20, 2026 06:50PM Form 4 Maze Therapeutics, Inc. For: Mar 20 Filed by: Bernstein Harold
Mar 12, 2026 04:51PM Form 4 Maze Therapeutics, Inc. For: Mar 10 Filed by: Bernstein Harold
Mar 10, 2026 04:33PM Form 144 Maze Therapeutics, Inc. Filed by: Bernstein Harold
Mar 3, 2026 04:45PM Form 4 Maze Therapeutics, Inc. For: Mar 02 Filed by: Bernstein Harold
Feb 4, 2026 04:26PM Form 4 Maze Therapeutics, Inc. For: Feb 02 Filed by: Bernstein Harold
Jan 9, 2026 04:51PM Form 4 Maze Therapeutics, Inc. For: Jan 07 Filed by: Bernstein Harold
Jan 6, 2026 04:32PM Form 4 Maze Therapeutics, Inc. For: Jan 02 Filed by: Bernstein Harold
Dec 31, 2025 04:23PM Form 4 Maze Therapeutics, Inc. For: Dec 29 Filed by: Bernstein Harold
Dec 29, 2025 04:28PM Form 144 Maze Therapeutics, Inc. Filed by: Bernstein Harold
Nov 6, 2025 07:01AM Maze Therapeutics presents drug data at kidney conference
Nov 6, 2025 07:00AM Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
Sep 24, 2025 04:24PM Form 4 Maze Therapeutics, Inc. For: Sep 22 Filed by: Bernstein Harold
Sep 11, 2025 07:30AM Maze Therapeutics reports positive phase 1 results for PKU, CKD drug
Sep 11, 2025 07:30AM Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (
Feb 7, 2025 08:01AM Maze Therapeutics (MAZE) Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
Feb 7, 2025 08:00AM Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
Jan 30, 2025 04:23PM Form 3 Maze Therapeutics, Inc. For: Jan 30 Filed by: Bernstein Harold